title: [Efficiency and safety of carvedilol treatment in high risk hypertensive patients].
abstract: OBJECTIVE
  To evaluate the efficiency and safety of carvedilol treatment in high risk hypertensive patients.
  
  
  METHODS
  Carvedilol was administered in 379 hypertensive patients with high risk factors such as NIDDM, lipid disorders or abnormal serum creatinine level and 364 primary hypertensive patients without risk factors. Before and after treatment with carvedilol, blood pressure, heart rate, serum glucose, lipid profile and serum creatinine level were tested.
  
  
  RESULTS
  After treatment, the blood pressure and heart rate were reduced significantly and there was no difference between the two groups. After treatment, the serum glucose, TC, TG and LDL in the high risk group, were reduced from 6.13, 5.37, 2.29 mmol/L and 3.04 to 5.80, 5.11, 2.05 and 2.87 mmol/L respectively (P < 0.001). TC was also reduced in the primary hypertensive group after treatment from 4.73 mmol/L to 4.69 mmol/L (P < 0.01). The efficiency rate of treatment in the high risk group and the primary hypertensive group was 97.75% and 98.32%; there is no statistical difference.
  
  
  CONCLUSIONS
  The efficiency and safety of carvedilol in the high risk hypertensive patients is same as in the primary hypertensive patients.
authors.affiliation: Department of Cardiology, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Xiu-li
authors.initials: XL
authors.lastname: Zhao
authors.forename: Dai-yi
authors.initials: DY
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077261:Carvedilol; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D002227:Carbazoles; D008055:Lipids; D011412:Propanolamines; D000077261:Carvedilol